Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 27, 2022 07:30 ET | Source: IN8bio, Inc

IN8bio to Present at Cantor Oncology & HemOnc Conference

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...
September 15, 2022 07:30 ET | Source: IN8bio, Inc

IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400

Agreement provides exclusive access to state-of-the-art GMP manufacturing suites to support Phase 2 clinical studiesPotential to expand the agreement to support commercial-scale manufacturing ...
September 13, 2022 07:30 ET | Source: IN8bio, Inc

IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference

NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...
September 08, 2022 07:30 ET | Source: IN8bio, Inc

IN8bio Appoints Michael R. Bishop, M.D., to Its Scientific Advisory Board

NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...
August 30, 2022 16:15 ET | Source: IN8bio, Inc

IN8bio to Present at September Investor and Scientific Conferences

NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...
August 19, 2022 09:20 ET | Source: IN8bio, Inc

IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering

NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
August 16, 2022 16:15 ET | Source: IN8bio, Inc

IN8bio Announces Closing of $10.25 Million Underwritten Public Offering of Common Stock

NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
August 12, 2022 16:15 ET | Source: IN8bio, Inc

IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Unveiled a new preclinical program focused on developing iPSC derived gamma-delta T cells and presented early findings at the ASGCT Annual Meeting.Presented data from Phase 1 clinical trial of INB-200...
August 11, 2022 22:05 ET | Source: IN8bio, Inc

IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock

NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
July 27, 2022 07:00 ET | Source: IN8bio, Inc

IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients

All three patients from the first cohort of high-risk relapsed acute-myeloid leukemia (AML) patients dosed to-date with INB-100 remain alive and progression-free after at least one year.Patients...